BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 35144477)

  • 1. Novel biochemical markers for non-invasive detection of pancreatic cancer.
    Hrabák P; Šoupal J; Kalousová M; Krechler T; Vočka M; Hanuš T; Petruželka L; Svačina Š; Žák A; Zima T
    Neoplasma; 2022 Mar; 69(2):474-483. PubMed ID: 35144477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
    Schultz NA; Dehlendorff C; Jensen BV; Bjerregaard JK; Nielsen KR; Bojesen SE; Calatayud D; Nielsen SE; Yilmaz M; Holländer NH; Andersen KK; Johansen JS
    JAMA; 2014 Jan 22-29; 311(4):392-404. PubMed ID: 24449318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The assessment of serum and diagnostic peritoneal lavage concentration of matrix metalloproteinase-2, matrix metalloproteinase-9, carbohydrate antigen 19-9, and carcinoembryonic antigen in patients with pancreatic cancer and chronic pancreatitis.
    Dranka-Bojarowska D; Lewinski A; Lekstan A; Gajda M; Ciosek J; Mrowiec S
    J Physiol Pharmacol; 2020 Oct; 71(5):. PubMed ID: 33571962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer.
    Jahan R; Ganguly K; Smith LM; Atri P; Carmicheal J; Sheinin Y; Rachagani S; Natarajan G; Brand RE; Macha MA; Grandgenett PM; Kaur S; Batra SK
    EBioMedicine; 2019 Apr; 42():375-385. PubMed ID: 30956167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentials of plasma NGAL and MIC-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer.
    Kaur S; Chakraborty S; Baine MJ; Mallya K; Smith LM; Sasson A; Brand R; Guha S; Jain M; Wittel U; Singh SK; Batra SK
    PLoS One; 2013; 8(2):e55171. PubMed ID: 23383312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer.
    Zhang J; Wang Y; Zhao T; Li Y; Tian L; Zhao J; Zhang J
    World J Surg Oncol; 2020 Feb; 18(1):31. PubMed ID: 32028958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of N-glycan markers that improve the performance of CA19-9 in pancreatic cancer.
    Zhao YP; Zhou PT; Ji WP; Wang H; Fang M; Wang MM; Yin YP; Jin G; Gao CF
    Clin Exp Med; 2017 Feb; 17(1):9-18. PubMed ID: 26714469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Verification of the effectiveness of fucosylated haptoglobin as a pancreatic cancer marker in clinical diagnosis.
    Kuwatani M; Kawakami H; Kubota Y; Kawakubo K; Ito YM; Togo S; Ikeda T; Kusama K; Kobayashi Y; Murata T; Sakamoto N
    Pancreatology; 2019 Jun; 19(4):569-577. PubMed ID: 31031206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a systematic review and meta-analysis.
    Zhao B; Zhao B; Chen F
    Eur J Gastroenterol Hepatol; 2022 Sep; 34(9):891-904. PubMed ID: 35913776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.
    Makawita S; Dimitromanolakis A; Soosaipillai A; Soleas I; Chan A; Gallinger S; Haun RS; Blasutig IM; Diamandis EP
    BMC Cancer; 2013 Sep; 13():404. PubMed ID: 24007603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
    Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
    Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis.
    Xue A; Scarlett CJ; Chung L; Butturini G; Scarpa A; Gandy R; Wilson SR; Baxter RC; Smith RC
    Br J Cancer; 2010 Jul; 103(3):391-400. PubMed ID: 20588270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New combined microRNA and protein plasmatic biomarker panel for pancreatic cancer.
    Yuan W; Tang W; Xie Y; Wang S; Chen Y; Qi J; Qiao Y; Ma J
    Oncotarget; 2016 Nov; 7(48):80033-80045. PubMed ID: 27713117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection.
    O'Brien DP; Sandanayake NS; Jenkinson C; Gentry-Maharaj A; Apostolidou S; Fourkala EO; Camuzeaux S; Blyuss O; Gunu R; Dawnay A; Zaikin A; Smith RC; Jacobs IJ; Menon U; Costello E; Pereira SP; Timms JF
    Clin Cancer Res; 2015 Feb; 21(3):622-31. PubMed ID: 24938522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinical study of serum human epididymis protein 4 (HE4) in the diagnosis of pancreatic cancer.
    Liu W; Liu W; Lin K; Liu Y; Hu H; Yang L
    Indian J Cancer; 2022; 59(2):223-229. PubMed ID: 34380855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study.
    Kaur S; Smith LM; Patel A; Menning M; Watley DC; Malik SS; Krishn SR; Mallya K; Aithal A; Sasson AR; Johansson SL; Jain M; Singh S; Guha S; Are C; Raimondo M; Hollingsworth MA; Brand RE; Batra SK
    Am J Gastroenterol; 2017 Jan; 112(1):172-183. PubMed ID: 27845339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum DJ-1 as a diagnostic marker and prognostic factor for pancreatic cancer.
    He XY; Liu BY; Yao WY; Zhao XJ; Zheng Z; Li JF; Yu BQ; Yuan YZ
    J Dig Dis; 2011 Apr; 12(2):131-7. PubMed ID: 21401899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
    Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
    Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum metabolomics differentiating pancreatic cancer from new-onset diabetes.
    He X; Zhong J; Wang S; Zhou Y; Wang L; Zhang Y; Yuan Y
    Oncotarget; 2017 Apr; 8(17):29116-29124. PubMed ID: 28418859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics.
    Yoneyama T; Ohtsuki S; Honda K; Kobayashi M; Iwasaki M; Uchida Y; Okusaka T; Nakamori S; Shimahara M; Ueno T; Tsuchida A; Sata N; Ioka T; Yasunami Y; Kosuge T; Kaneda T; Kato T; Yagihara K; Fujita S; Huang W; Yamada T; Tachikawa M; Terasaki T
    PLoS One; 2016; 11(8):e0161009. PubMed ID: 27579675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.